Public consultation: New classification of L04A Immunosuppressants
Published Thursday May 5 2022

New classification of L04A Immunosuppressants

A revision of the classification of the immunosuppressants in L04A IMMUNOSUPPRESSANTS, is needed due to the increasing number of new immunosuppressants being developed. A revision of the current classification in L04A was discussed by the WHO International Working Group for Drug Statistics Methodology at the latest meetings in October 2021 and March 2022. The Working Group would like to get feedback from the users of the ATC/DDD system on the proposed new classification to ensure its usefulness.

Two proposals are provided for discussion and feedback. The first is based on pharmacology and mechanism of action, the second proposal is a hybrid option based on pharmacology, mechanism of action, and indications. The classification of drugs into disease-specific groups could be a benefit in drug utilisation analyses. Currently, two disease-specific fields have been identified as possible ATC groups; immunosuppressants for transplant rejection and immunosuppressantsfor multiple sclerosis.

See proposals here.

The proposed new classification is intended to be implemented in the ATC Index 2024.

Deadline 15^th of August 2022
We would appreciate your feedback related to the new proposed classification. If you have alternative suggestions for ATC classification, we would appreciate your comments as soon as possible and no later than the 15^th of August 2022.

Please send your comments to .

WHO Collaborating Centre for Drug Statistics Methodology
Oslo, May 2, 2022